国产午夜福利片1000无码丨人妻国产成人久久av免费高清丨午夜做受视频试看6次丨日韩av不卡一区在线免费观看丨在线观看精品三级欧美

Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯免疫試劑盒
  4. Mouse Apolipoprotein A-IV(APOA4) ELISA kit

Mouse Apolipoprotein A-IV(APOA4) ELISA kit

  • 中文名稱：
    小鼠載脂蛋白A-IV(APOA4)酶聯免疫試劑盒
  • 貨號：
    CSB-EL001916MO
  • 規格：
    96T/48T
  • 價格：
    ￥3600/￥2500
  • 促銷：
  • 其他：

產品詳情

  • 產品描述：
    小鼠載脂蛋白A-IV(APOA4)酶聯免疫試劑盒（CSB-EL001916MO）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織勻漿樣本中的APOA4含量。試劑盒檢測范圍為0.27 ng/ml-200 ng/ml，該產品可應用于小鼠模型中脂質代謝機制研究、營養干預對載脂蛋白表達的影響評估，或心血管疾病動物模型的組織蛋白水平分析，為探索APOA4在能量代謝、炎癥調節等領域的生物學功能提供可靠工具。本品僅用于科研，不用于臨床診斷，產品具體參數及操作步驟詳見產品說明書。
  • 別名：
    Apoa4 ELISA Kit; Apolipoprotein A-IV ELISA Kit; Apo-AIV ELISA Kit; ApoA-IV ELISA Kit; Apolipoprotein A4 ELISA Kit
  • 縮寫：
    APOA4
  • Uniprot No.：
  • 種屬：
    Mus musculus (Mouse)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測范圍：
    12.5 ng/mL-800 ng/mL
  • 靈敏度：
    6.25 ng/mL
  • 反應時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領域：
    Cancer
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：

    Intra-assay Precision (Precision within an assay): CV%<8%

    		      

    Three samples of known concentration were tested twenty times on one plate to assess.

    		  

    Inter-assay Precision (Precision between assays): CV%<10%

    		      

    Three samples of known concentration were tested in twenty assays to assess.

    		    
  • 線性度：

    To assess the linearity of the assay, samples were spiked with high concentrations of mouse APOA4 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

    　

    Sample

    Serum(n=4)

    		  

    1:1

    Average %

    101

    		  

    Range %

    97-106

    		  

    1:2

    Average %

    106

    		  

    Range %

    100-114

    		  

    1:4

    Average %

    98

    		  

    Range %

    94-103

    		  

    1:8

    Average %

    90

    		  

    Range %

    85-95

    		  
  • 回收率：

    The recovery of mouse APOA4 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    		  

    Serum (n=5)

    96

    91-103

    		  

    EDTA plasma (n=4)

    91

    86-96

    		  
  • 標準曲線：

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

     
    		           

    ng/ml

    OD1

    OD2

    Average

    Corrected

    		  

    200

    2.297

    2.334

    2.316

    2.124

    		  

    66.6

    1.895

    1.767

    1.831

    1.639

    		  

    22.2

    1.214

    1.228

    1.221

    1.029

    		  

    7.4

    0.645

    0.629

    0.637

    0.445

    		  

    2.46

    0.388

    0.371

    0.379

    0.188

    		  

    0.82

    0.251

    0.253

    0.252

    0.060

    		  

    0.27

    0.214

    0.204

    0.209

    0.017

    		  

    0

    0.189

    0.195

    0.192

    　

    		  
  • 數據處理：
  • 貨期：
    3-5 working days

產品評價

靶點詳情

  • 功能：
    May have a role in chylomicrons and VLDL secretion and catabolism. Required for efficient activation of lipoprotein lipase by ApoC-II; potent activator of LCAT. Apoa-IV is a major component of HDL and chylomicrons.
  • 基因功能參考文獻：
    1. This study uncovers an anti-sense lncRNA (APOA4-AS), which is co-expressed with APOA4, and concordantly and specifically regulates APOA4 expression both in vitro and in vivo with the involvement of HuR. PMID: 27131369
    2. Our findings may throw light on the function of ApoA4 in inflammatory responses and acute-phase reactions, as well as the development of SERPINA3 relative diseases. PMID: 28412351
    3. Very Low Density Lipoprotein (VLDL) assembly and CREBH activation play key roles in the response to hepatic steatosis by up-regulating apoA-IV and promoting assembly and secretion of larger, more triglyceride - enriched VLDL particles. PMID: 27655915
    4. It was suggested that increased ileal GPR119 is a potential mechanism by which GLP-1 secretion is enhanced in apoA-IV-/- mice. PMID: 26294669
    5. these data suggest that apoA-IV is not necessary for the metabolic improvements shown with VSG, but also suggest an interesting role for apoA-IV in regulating macronutrient preference and hepatic triglyceride levels. PMID: 25157093
    6. These results reveal ApoA-IV as a novel follicle-associated epithelium-specific marker especially in the upper small intestine of adult mice. PMID: 24838500
    7. transcriptional regulation of apolipoprotein A-IV by the transcription factor CREBH PMID: 24598141
    8. apoA-IV inhibits hepatic gluconeogenesis by decreasing Glc-6-Pase and PEPCK gene expression through NR1D1. PMID: 24311788
    9. Hepatic steatosis in mice induces hepatic apoA-IV expression, which in turn promotes lipoprotein particle expansion and reduces hepatic lipid burden without increasing the number of secreted atherogenic apoB-containing lipoprotein particles. PMID: 24030551
    10. Data indicate that plasma lipids, lipid absorption, and microsomal triglyceride transfer protein (MTP), FoxO1, and FoxA2 levels are lower at night and at mealtime in apoAIV-/- mice. PMID: 23729668
    11. a novel function of apoA-IV in the biogenesis of discrete HDL-A-IV particles with the participation of ABCA1 and LCAT PMID: 23132909
    12. peripheral apo AIV requires an intact CCK system and vagal afferents to activate neurons in the hindbrain to reduce food intake PMID: 23027805
    13. results suggest that apoA-IV may provide a therapeutic target for the regulation of glucose-stimulated insulin secretion and treatment of diabetes PMID: 22619326
    14. Data show that ApoA4 is a true target gene of LUMAN in bone marrow-derived DCs (BMDCs). PMID: 22209087
    15. These data suggest that Apoa4 has a previously unknown role in mediating the metabolism of chylomicrons, and therefore may be important in regulating plasma lipid metabolism. PMID: 22207575
    16. apoA-IV may play a unique role in integrating feeding behavior, intestinal lipid absorption, and energy storage PMID: 21840868
    17. ApoA-IV deficiency increases Abeta deposition and results in cognitive damage in the mouse model. PMID: 21356380
    18. ApoA-IV restriction to enterocyte is controlled by a new hormone-response element. PMID: 12105231
    19. Results provide the first direct support for the hypothesis that apolipoprotein A-IV is an endogenous anti-inflammatory protein. PMID: 15254593
    20. apo A-IV and apo A-V are positive acute-phase proteins in mouse HDL PMID: 15306172
    21. results demonstrate that apoA-IV is a direct ERRalpha target gene and suggest a function for ERRalpha in intestinal fat transport, a crucial step in energy balance PMID: 15466464
    22. the induction of apoA-IV expression in fasting and diabetes likely involves PGC-1 alpha-mediated coactivation of HNF-4 alpha in addition to glucocorticoid-dependent actions PMID: 16929032
    23. The hypothalamic apo A-IV is regulated by leptin, at least partially, via the STAT3 signaling pathway. PMID: 17363460
    24. Role for apo A-IV and CCK(1)R in PYY(3-36)-induced activation of vagal afferent pathway and inhibition of gastric emptying, but this is likely not pathway mediating effects of PYY(3-36) on food intake. PMID: 17641001
    25. the apoCIII enhancer contributes to the maintenance of an active chromatin subdomain of the apoAI/CIII/AIV genes, but not apoAV PMID: 18678879

    顯示更多

    收起更多

  • 亞細胞定位：
    Secreted.
  • 蛋白家族：
    Apolipoprotein A1/A4/E family
  • 組織特異性：
    Secreted in plasma.
  • 數據庫鏈接：

    KEGG: mmu:11808

    STRING: 10090.ENSMUSP00000034585

    UniGene: Mm.4533